Prosecution Insights
Last updated: April 19, 2026

Sigilon Therapeutics Inc.

8 pending office actions

Portfolio Summary

8
Total Pending OAs
3
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18276010 COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE ZAHORIK, AMANDA MARY 1636 Non-Final OA Aug 04, 2023
18019664 HETEROARYL AND HETEROCYCLYL COMPOUNDS STEVENS, MARK V 1613 Final Rejection Feb 03, 2023
18018371 GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF SCHLIENTZ, NATHAN W 1616 Non-Final OA Jan 27, 2023
17764096 METHODS OF EVALUATING POLYPEPTIDE-MODIFIED POLYMERS IN COMPOSITIONS GZYBOWSKI, MICHAEL STANLEY 1798 Non-Final OA Mar 25, 2022
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 1638 Non-Final OA Sep 24, 2021
17280802 IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS BEANE, RANDALL L 1654 Final Rejection Mar 26, 2021
17045137 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS BABSON, NICOLE PLOURDE 1619 Final Rejection Oct 02, 2020
16651892 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS WEIDNER, ADAM M 1675 Non-Final OA Mar 27, 2020

Managing Sigilon Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month